SynthesisTranslational vision science & technology2026
Circulating Inflammatory Proteins and Fuchs Endothelial Corneal Dystrophy: A Mendelian Randomization and Bioinformatics-Based Investigation.
Synthesis in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Fuchs endothelial corneal dystrophy (FECD) is an age-related ocular disorder characterized by gradual loss of corneal endothelial cells, with growing evidence implicating chronic inflammation in its pathogenesis. This study aims to investigate causal relationships between circulating inflammatory proteins (IPs) and FECD. Methods: We performed bidirectional two-sample Mendelian randomization (MR) analysis using IP summary statistics (N = 14,824) and FECD data from the GWAS Catalog (N = 448,712). Key findings were then validated in two independent FECD datasets and subjected to meta-analysis. Differential gene expression profiles were explored using GEO datasets and an in vitro assay. Results: The initial MR analysis identified potential causal links for three IPs. Only TNFRSF11B demonstrated a robust risk effect confirmed by a subsequent cross-cohorts meta-analysis (odds ratio = 1.193; 95% confidence interval, 1.039-1.369; P-meta = 0.01212). In contrast, the associations for MIP-1β and NRTN were limited by marginal statistical significance and inconsistent replication directions, respectively. Transcriptomic profiling further confirmed elevated TNFRSF11B expression in FECD-affected tissues. TNFRSF11B expression was also increased in human corneal endothelial cells upon H2O2 exposure in vitro. Conclusions: This study highlights the involvement of inflammatory pathways in FECD pathogenesis and identifies genetically predicted TNFRSF11B levels as a robust risk factor. Supported by consistent meta-analysis and expression validation, TNFRSF11B emerges as a high-priority candidate biomarker and a plausible therapeutic target worthy of further investigation. Translational Relevance: Our findings advance the understanding of the genetic architecture of inflammatory mechanisms in FECD and provide a strong rationale for exploring TNFRSF11B inhibition as a novel therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.